Michael Klichinsky
Lawrence Lamb
Alfonso Quintas-Cardama
Gary C. Du Moulin, PhD
Biren Mistry
Stephan Grupp MD
David Epstein
Dr Yangbing Zhao
Dr. Yangbing Zhao is the Director of the T Cell Engineering Laboratory (TCEL), Center for Cellular Immunotherapies at the University of Pennsylvania. He received an MD and PhD in Immunology from the Third Medical University in Chongqing, China. From 1996 – 2000, he was a visiting scientist at The Weizmann Institute of Science in Rehovot, Israel, where he studied tolerance induction through genetically engineered T cells for allogeneic bone marrow transplantation. For the next two years he was a research associate at Duke University Medical Center, where he worked on RNA transfected dendritic cell vaccines against tumors. In 2003, he joined Dr. Steven Rosenberg’s group as a senior research fellow at the Surgery Branch of the National Cancer Institute, where his research work directly led to clinical trials of treating cancer patients with TCR or CAR engineered T cells against NY-ESO-1, Her2/Neu, CD19 or VEGFR. He joined the faculty of the Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine in 2009 as the Director of TCEL. His Laboratory’s research and development work has led to multiple clinical trials for the treatment of solid tumors with genetically engineered T cells against mesothelioma, pancreatic cancer, breast cancer and glioblastoma.
Andrew Allen
